A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the
co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum
tolerated dose and/or Recommended Phase II dose of the combination and b) to assess the
efficacy of the co-administration of LDE225 and INC424 on spleen volume reduction.